Articles Tagged: Federal Trade Commission
The Federal Trade Commission has announced what it calls a major antitrust settlement with Caremark, resolving a closely watched case against one of the country’s largest pharmacy benefit managers. Even without the full settlement details in hand, the development is important: it signals that the FTC is continuing to press competition theories aimed at the role PBMs play in drug pricing, formulary design, and pharmacy reimbursement.
For antitrust and healthcare lawyers, the significance goes well beyond a single company.
On March 30th,
the Federal Trade Commission filed a lawsuit against drug manufacturer Endo
Pharmaceuticals, alleging that Endo is paying generic drug manufacturers in order to
delay the release of lower cost generic versions of their drugs, Opana ER and
Lidoderm.
Generic drugs
come to market when the patents on name brand drugs expire.
Stay Connected